Non-Hodgkin Lymphoma
News
Drug granted priority review for CTCL
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) seeking approval for...
News
New cancer diagnosis linked to arterial thromboembolism
Patients newly diagnosed with cancer may have a short-term increased risk of arterial thromboembolism, according to a new study. The research...
News
Analysis reveals poor outcomes in refractory DLBCL
Results from the SCHOLAR-1 study revealed poor outcomes of salvage therapy in patients with refractory diffuse large B-cell lymphoma (DLBCL). This...
News
FDA grants acalabrutinib breakthrough designation
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to acalabrutinib, a BTK inhibitor being developed to treat...
News
Developing better mouse models
Researchers say they have developed a new approach to model human immune variation that overcomes the limitations of traditional mouse models....
Conference Coverage
High ORR with sequential regimen in CLL
LUGANO, SWITZERLAND—A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or...
News
CHMP recommends new indication for obinutuzumab
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
News
Modified, CB-derived NK cells target CLL and BL
Natural killer (NK) cells derived from cord blood (CB) can be modified to fight chronic lymphocytic leukemia (CLL) and Burkitt lymphoma (BL),...
Conference Coverage
GAD-M produces high ORR in treatment-naïve ENKTL
LUGANO, SWITZERLAND—A 4-drug regimen has demonstrated efficacy in a phase 2 trial of patients with treatment-naïve extranodal natural killer/T-...
Conference Coverage
CTL019 produces responses in rel/ref DLBCL
The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory...
Conference Coverage
Combo demonstrates activity in CLL/SLL and FL
LUGANO, SWITZERLAND—Results of a phase 1 study suggest a 2-drug combination may be safe and effective in patients with chronic lymphocytic...